Publication Details
Abstract
The safety and efficacy of drug treatment for painful temporomandibular joint (TMJ) dysfunction depend on the appropriateness of prescribing, the pharmacokinetics of the drug, and the patient's condition. This narrative review compares the main drug classes with regard to elimination half-life, hepatic metabolism, excretion pathways, and the effects of hepatic and renal impairment. It discusses nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, muscle relaxants, antidepressants, gabapentinoids, benzodiazepines, tramadol, and prednisolone. Metabolism is distinguished from excretion, as are plasma elimination half-life and duration of clinical action. Hydrophilicity alone does not determine drug safety, and hepatic metabolism does not preclude renal excretion of metabolites. Organ function, drug interactions, and the risk of accumulation should be considered, while pharmacotherapy should be combined with measures to restore mandibular function. No single drug is universally the safest option for all patients with painful TMJ dysfunction.